ince its discovery in 1996, the adipose-derived plasma protein adiponectin has been the object of a growing research interest, witnessed by more than 3,500 related publications. Although adiponectin is produced by the adipose tissue, its secretion is strongly inhibited by fat accumulation, especially at the visceral level. Unlike other adipocytokines, adiponectin has important beneficial pleiotropic biological functions that are relevant to the pathogenesis of metabolic syndrome, diabetes, and cardiovascular diseases.
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Hyposecretion of defensive adipocytokines (e.g., adiponectin) is a major consequence of unhealthy lifestyle factors, such as excess caloric intake and physical inactivity and the resulting visceral fat accumulation, though genetic factors may also have a role in modulating adiponectin and its effects. More recently, it has been hypothesized that low adiponectin levels might be involved in the development of hypertension. A number of cross-sectional clinical studies have demonstrated the existence of an inverse relationship between serum adiponectin concentration and blood pressure. [1] [2] [3] In a recent prospective, nested case-control study by Chow et al., 4 low adiponectin levels were found to predict the future occurrence of hypertension in a normotensive cohort. Despite the limitations related to the casecontrol design and a limited sample size, that study raises the possibility that low adiponectin levels might play a significant role in the pathogenesis of human hypertension.
In the current issue of the Journal, Li et al. confirm the above findings in a large Asian population sample, and shed some more light on the link between adiponectin and hypertension. 5 The authors examined 1,048 nondiabetic subjects drawn from 478 families, and found that low plasma adiponectin was an independent predictor of the hypertensive status. The effect of adiponectin was additional to that of age, sex, and insulin sensitivity measured noninvasively as either standardized homeostasis model assessment or insulin sensitivity index (0, 120) . Moreover, in a subset of 349 normotensive subjects the authors found that an independent inverse relation between adiponectin and blood pressure was apparent only among obese subjects, and not in nonobese individuals.
The pathophysiological links between obesity and hypertension are complex and incompletely understood. Hypertension and obesity share complex pathophysiological interrelationships, and several potential mechanisms may underlie the relation between hypoadiponectinemia and hypertension. 6 In this regard, the suggestion that the relation between adiponectin and blood pressure might depend on obesity 5 is intriguing.
Does this study 5 prove the hypothesis that adiponectin is a key mediator of the relationship between obesity and high blood pressure? These findings should be interpreted in the context of their limitations. Unfortunately, the authors did not include body mass index in their main analysis, and performed obesity-specific analysis only in normotensives. The demonstration of an association between adiponectin and blood pressure also in hypertensive subjects would have increased the clinical impact of the study. Given that adiponectin levels are substantially different in men and women, it would be desirable to carry out separate analyses in the two genders, although this would reduce statistical power. Moreover, the Authors were not able to differentiate lower-weight forms of adiponectin from the high-molecular complexes, which might have different biological actions.
Overall, the findings of the present study add to the current literature by further suggesting that low adiponectin levels could be an important underlying factor on the way leading from obesity to hypertension. The definitive demonstration of the role of adiponectin in this respect needs large, properly designed prospective studies aiming at addressing the value of hypoadiponectinemia as a predictor of hypertension.
